Company Overview and News
Vanadium market news - Vanadium market expected to grow, fueled by strong steel and increasing energy storage demands.
AVL SRHYY GLCNF KRC PRPCF TON NMT CCC APPPF SYR EFR AEE RDRUY ATVVF UUUU AUEEF LGO APAFF LGORF AMVMF SYAAF RRSSF BSHVF CCCCF bmn
Vanadium market news - Navigant - "VRB to be one of the fastest growing electrochemical storage technology sets over the next decade."
AVL SRHYY KRC PRPCF TON NMT CCC APPPF SYR EFR AEE RDRUY UUUU ATVVF AUEEF LGO APAFF LGORF AMVMF SYAAF RRSSF BSHVF CCCCF bmn
2018-06-29 seekingalpha - 1
Vanadium market news - "We are already in a market deficit with no known strategic stockpiles. This is only going to be further exacerbated as rebar companies begin complying."
AVL SRHYY KRC PRPCF MALRY TON MIN NMT SYR EFR AEE RDRUY UUUU ATVVF AUEEF LGO APAFF LGORF AMVMF SYAAF RRSSF BSHVF MALRF bmn
Aura Energy Limited's (LON:AURA) Peter Reeve tells Proactive that the firm is aiming to complete a definitive feasibility study for its Tiris Uranium project in Mauritania by the end of 2018.
Vanadium company news - Triton to fast track vanadium study at Nicanda Hill vanadium resources 1.44billion tonnes. Aura Energy Reports 90 Million Tonne Vanadium Zone at Haggan.
AVL SRHYY KRC PRPCF TON LGORF NMT AMVMF SYAAF RRSSF BSHVF SYR EFR AEE RDRUY UUUU ATVVF AUEEF bmn LGO BAM APAFF
Vanadium Flow Batteries are ideal for energy storage where their scalability reduces cost, and offers much longer battery life (as many as 10-100,000 cycles).
AVL SRHYY KRC PRPCF TON LGORF NMT SYAAF RRSSF BSHVF SYR EFR AEE RDRUY UUUU ATVVF AUEEF bmn LGO
Vanadium market news - Mining legend Robert Friedland states: "We think there’s a revolution coming in vanadium redox flow batteries."
AVL AVC SRHYY KRC PRPCF TON LGORF NMT AVCVF PFS SYAAF RRSSF BSHVF SYR EFR AEE RDRUY UUUU ATVVF AUEEF bmn LGO
Aura Energy Ltd (ASX:AEE) (LON:AURA) has completed a heavily oversubscribed capital raising priced at 1.9 cents which has secured $3.7 million in funding.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to ASX:AEE / AURA ENERGY LIMITED on message board site Silicon Investor.
|AEE vse (Antler Resources Ltd.)||AEE vse (Antler Resources Ltd.)||AEE vse (Antler Resources Ltd.)|